Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07224399 · ClinicalTrials.gov registry record · Phase 1

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women

A Phase 1 study of Overweight or Obesity and Healhty, sponsored by BrightGene Bio-Medical Technology Co..

Recruiting
Registry status
Phase 1
Development phase
60
Enrollment target
1
Study location

NCT07224399: Recruiting Phase 1 study of Overweight or Obesity and Healhty, sponsored by BrightGene Bio-Medical Technology Co..

NCT07224399 is a Phase 1 study of Overweight or Obesity and Healhty that is actively recruiting participants, run by BrightGene Bio-Medical Technology Co.. The registered enrollment target is 60 participants, below the 31,711-participant average among 32 other Overweight or Obesity trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07224399, a Phase 1 study of Overweight or Obesity and Healhty, is actively recruiting participants, sponsored by BrightGene Bio-Medical Technology Co..

RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

This is a Phase 1, single-center, double-blind, placebo-controlled, dose-escalation study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM1812 following single and multiple SC administrations in normal to overweight or obese but otherwise healthy subjects.

Conditions Studied

Overweight or Obesity Healhty

Interventions

  • DRUG Placebo
  • DRUG BGM1812

Study Locations (1)

Maryland

  • Pharmaron CPC, Inc - Baltimore

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-10-09
Est. Completion 2026-05-15
Phase Phase 1

Sponsor

BrightGene Bio-Medical Technology Co.

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07224399

The ClinicalTrials.gov registry entry for NCT07224399 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 31,711-participant average among 32 other Overweight or Obesity trials with a reported enrollment target (100% lower). The listed sponsor is BrightGene Bio-Medical Technology Co., which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Overweight or Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07224399 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT07224399 about?

NCT07224399 is a clinical study titled "Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women". This is a Phase 1, single-center, double-blind, placebo-controlled, dose-escalation study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM1812 following single and multiple SC administrations in normal to overweight or obe...

What is the current status of trial NCT07224399?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-10-09. Estimated completion is 2026-05-15.

What conditions does trial NCT07224399 study?

This clinical trial studies the following conditions: Overweight or Obesity, Healhty.

What interventions are being tested in trial NCT07224399?

The interventions under investigation include: Placebo (DRUG), BGM1812 (DRUG).

Who is sponsoring clinical trial NCT07224399?

This trial is sponsored by BrightGene Bio-Medical Technology Co., which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07224399 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Overweight or Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Overweight or Obesity

All registered trials for this condition

Healhty

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.